BioMedNewsBreaks Archive - Page 79 of 240

TuesdayJan 16, 2024 2:38 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer’s disease and age-related macular degeneration (‘AMD’),” said Eric A. Adams, InMed president and CEO.…

TuesdayJan 16, 2024 2:27 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released a message for its shareholders from CEO Mark Dybul. In the message, Dybul provides an update about key developments the company experienced during 2023, including signing a definitive agreement to combine with the European-based, cutting-edge artificial-intelligence (“AI”) company GEDi Cube; GEDi Cube’s partnership with NVIDIA to expand its multiomic capabilities to multimodal; and consistently achieving “the holy grail of cancer research” in preclinical studies. The company has also scheduled a shareholder meeting on Jan. 25, 2024, to vote…

FridayJan 12, 2024 2:30 pm

BioMedNewsBreaks — Bruush Oral Care Inc. (NASDAQ: BRSH) Closes Private Placement, Enters into Purchase Agreement

Bruush Oral Care (NASDAQ: BRSH), an oral-care company that is disrupting the space by reducing the barriers between consumers and access to premium oral-care products, has closed on a private placement transaction and a registration rights agreement with Generating Alpha Ltd. for aggregate gross proceeds of $500,000; the company also entered into another securities purchase agreement with Generating Alpha. According to the filing with the U.S. Securities and Commission, Bruush Oral Care has agreed to sell a convertible promissory note in an aggregate principal amount of up to $6 million. EF Hutton acted as placement agent for the financing. To…

FridayJan 12, 2024 2:09 pm

BioMedNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Partners with Navix Health to Provide Next-Generation Digital Healthcare Platform

SOBRSafe (NASDAQ: SOBR), a company that is pioneering noninvasive, humane and hygienic alcohol detection with a priority on safety, support and accountability, has been selected by Navix Health, a leading provider of innovative healthcare technologies, as its exclusive alcohol data partner. According to the announcement, Navix Health will integrate SOBRsafe's advanced alcohol monitoring technology into its proprietary Navix Hub(TM). The exclusive hub is a fully unified facility and practice management software for behavioral health. The integration of the SOBRsafe technology, which will enable Navix Hub users to augment current operations with touch-based alcohol monitoring, is aimed to enhance patient care,…

FridayJan 12, 2024 1:18 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an unmet need in the industry… PaxMedica is on a mission to help, reduce and modulate some of the more challenging aspects of ASD. The company hopes to enable people with autism to integrate their behavior with others more successfully and improve their quality of life,”…

TuesdayJan 09, 2024 1:27 pm

BioMedNewsBreaks– SOHM Inc. (SHMN) Announces Filing of Provisional Patent for ABBIE Smart Gene Editing Technology

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has filed a provisional patent application on its ABBIE Smart Gene-Editing platform. According to the announcement, the platform uses the latest enzymes and guide RNAs to resolve off-target gene-editing limitations. Gene therapy modifies or manipulates the expression of a gene or alters the biological properties of living cells for therapeutic use and has become a critical tool for treating genetic diseases. One of the challenges of gene therapy, however, is ensuring that gene edits happen at the intended site and not…

TuesdayJan 09, 2024 1:17 pm

BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew something great was in the making,” said Branded Legacy CEO David Oswald. “It is a rare enough thing to find a company motivated primarily by the positive impact they can make on society. We are…

MondayJan 08, 2024 2:19 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (“ALS”) and multiple sclerosis (“MS”), today reported new CNM-Au8(R) results from the long-term open label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow-up. After completion of the double-blind period, study participants were offered to continue on CNM-Au8 30mg for up to an additional 96-weeks in the LTE. Analyses were reported for the modified intent…

ThursdayJan 04, 2024 2:14 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Releases Shareholder Letter

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (“I&I”) biological products, has released a letter from its CEO, Amir Reichman. In the letter, Reichman summarizes the company’s 2023 accomplishments and looks forward to 2024. According to the letter, company highlights for the year include a recently completed ex-vivo study that indicates the potential of SCNI’s anti-IL-17 VHH antibody (“NanoAb”) to effectively and conveniently treat mild to moderate plaque psoriasis; the launch of Scinai Bioservices, the company’s boutique, end-to-end CDMO (“CDMO”) business unit, which will focus on assisting biotech companies to bring their products to market; capital infusions that…

ThursdayJan 04, 2024 12:20 pm

BioMedNewsBreaks – Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) Announces Pricing of US$20M Public Offering

Profound Medical (TSX: PRN) (NASDAQ: PROF) recently announced the pricing of its underwritten public offering of 2,666,667 common shares, each at a price to the public of US$7.50, led by health care-focused institutional investors. Of approximately US$20,000,000 in gross proceeds from the offering, the company intends to use net proceeds to fund the continued commercialization of the TULSA-PRO(R) system in the United States, to fund the continued development and commercialization of the TULSA-PRO system and the Sonalleve(R) system globally, as well as for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

BioMedNewsBreaks — Bruush Oral Care Inc. (NASDAQ: BRSH) Closes Private Placement, Enters into Purchase Agreement

BioMedNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Partners with Navix Health to Provide Next-Generation Digital Healthcare Platform

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

BioMedNewsBreaks– SOHM Inc. (SHMN) Announces Filing of Provisional Patent for ABBIE Smart Gene Editing Technology

BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Releases Shareholder Letter

BioMedNewsBreaks – Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) Announces Pricing of US$20M Public Offering

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search